SC
AUPH icon

Stephens Consulting’s Aurinia Pharmaceuticals AUPH Stock Holding History

Stephens Consulting’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45
Closed -$362 – 1271
2025
Q1 		$362 Buy
+45
New +$365 ﹤0.01% 1254

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stephens Consulting's AUPH Position: Q2 2025 in Review

Stephens Consulting sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 45 shares — an estimated $362 sold.

Stephens Consulting first reported a position in AUPH in Q1 2025 and held it in 1 quarter. The position peaked at $362 in Q1 2025. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Stephens Consulting reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 45 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $362.
  • Stephens Consulting first reported a position in Aurinia Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Aurinia Pharmaceuticals position peaked at $362 in Q1 2025.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.